Aim­ing at main­stream mar­kets, ra­dio­phar­ma­ceu­ti­cal part­ners en­gi­neer $260M cash deal

When Point Bio­phar­ma geared up to launch a Phase III tri­al for its PS­MA-tar­get­ing ra­di­oli­gand ther­a­py, one of the first things it did was to part­ner with Lan­theus, the mak­er of a then-in­ves­ti­ga­tion­al PET imag­ing agent that can vi­su­al­ize the pres­ence of the prostate-spe­cif­ic mem­brane anti­gen in pa­tients.

Two years lat­er — with Lan­theus’ imag­ing agent now of­fi­cial­ly ap­proved and Point’s tri­al well un­der­way — the com­pa­nies are form­ing an even tighter bond.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER